Research ArticleArticle
Drug Efflux Transporter Multidrug Resistance-Associated Protein 5 Affects Sensitivity of Pancreatic Cancer Cell Lines to the Nucleoside Anticancer Drug 5-Fluorouracil
Praveen K. Nambaru, Tobias Hübner, Kathleen Köck, Steffen Mews, Markus Grube, Léa Payen, Jérôme Guitton, Matthias Sendler, Gabriele Jedlitschky, Christian Rimmbach, Dieter Rosskopf, Dariusz W. Kowalczyk, Heyo K. Kroemer, Frank U. Weiss, Julia Mayerle, Markus M. Lerch and Christoph A. Ritter
Drug Metabolism and Disposition January 2011, 39 (1) 132-139; DOI: https://doi.org/10.1124/dmd.110.033613
Praveen K. Nambaru
Research Center of Pharmacology and Experimental Therapeutics (P.K.N., T.H., K.K., M.G., G.J., C.R., D.R., H.K.K., C.A.R.), Institute of Pharmacy (S.M., C.A.R.), and Department of Internal Medicine A (M.S., F.U.W., J.M., M.M.L.), Ernst-Moritz-Arndt-University, Greifswald, Germany; Laboratoire de Toxicologie, Faculté de Pharmacie de Lyon, Université de Lyon, Lyon, France (L.P., J.G.); and Department of Tumor Immunology, Wielkopolska Cancer Center, Poznan, Poland (D.W.K.)
Tobias Hübner
Research Center of Pharmacology and Experimental Therapeutics (P.K.N., T.H., K.K., M.G., G.J., C.R., D.R., H.K.K., C.A.R.), Institute of Pharmacy (S.M., C.A.R.), and Department of Internal Medicine A (M.S., F.U.W., J.M., M.M.L.), Ernst-Moritz-Arndt-University, Greifswald, Germany; Laboratoire de Toxicologie, Faculté de Pharmacie de Lyon, Université de Lyon, Lyon, France (L.P., J.G.); and Department of Tumor Immunology, Wielkopolska Cancer Center, Poznan, Poland (D.W.K.)
Kathleen Köck
Research Center of Pharmacology and Experimental Therapeutics (P.K.N., T.H., K.K., M.G., G.J., C.R., D.R., H.K.K., C.A.R.), Institute of Pharmacy (S.M., C.A.R.), and Department of Internal Medicine A (M.S., F.U.W., J.M., M.M.L.), Ernst-Moritz-Arndt-University, Greifswald, Germany; Laboratoire de Toxicologie, Faculté de Pharmacie de Lyon, Université de Lyon, Lyon, France (L.P., J.G.); and Department of Tumor Immunology, Wielkopolska Cancer Center, Poznan, Poland (D.W.K.)
Steffen Mews
Research Center of Pharmacology and Experimental Therapeutics (P.K.N., T.H., K.K., M.G., G.J., C.R., D.R., H.K.K., C.A.R.), Institute of Pharmacy (S.M., C.A.R.), and Department of Internal Medicine A (M.S., F.U.W., J.M., M.M.L.), Ernst-Moritz-Arndt-University, Greifswald, Germany; Laboratoire de Toxicologie, Faculté de Pharmacie de Lyon, Université de Lyon, Lyon, France (L.P., J.G.); and Department of Tumor Immunology, Wielkopolska Cancer Center, Poznan, Poland (D.W.K.)
Markus Grube
Research Center of Pharmacology and Experimental Therapeutics (P.K.N., T.H., K.K., M.G., G.J., C.R., D.R., H.K.K., C.A.R.), Institute of Pharmacy (S.M., C.A.R.), and Department of Internal Medicine A (M.S., F.U.W., J.M., M.M.L.), Ernst-Moritz-Arndt-University, Greifswald, Germany; Laboratoire de Toxicologie, Faculté de Pharmacie de Lyon, Université de Lyon, Lyon, France (L.P., J.G.); and Department of Tumor Immunology, Wielkopolska Cancer Center, Poznan, Poland (D.W.K.)
Léa Payen
Research Center of Pharmacology and Experimental Therapeutics (P.K.N., T.H., K.K., M.G., G.J., C.R., D.R., H.K.K., C.A.R.), Institute of Pharmacy (S.M., C.A.R.), and Department of Internal Medicine A (M.S., F.U.W., J.M., M.M.L.), Ernst-Moritz-Arndt-University, Greifswald, Germany; Laboratoire de Toxicologie, Faculté de Pharmacie de Lyon, Université de Lyon, Lyon, France (L.P., J.G.); and Department of Tumor Immunology, Wielkopolska Cancer Center, Poznan, Poland (D.W.K.)
Jérôme Guitton
Research Center of Pharmacology and Experimental Therapeutics (P.K.N., T.H., K.K., M.G., G.J., C.R., D.R., H.K.K., C.A.R.), Institute of Pharmacy (S.M., C.A.R.), and Department of Internal Medicine A (M.S., F.U.W., J.M., M.M.L.), Ernst-Moritz-Arndt-University, Greifswald, Germany; Laboratoire de Toxicologie, Faculté de Pharmacie de Lyon, Université de Lyon, Lyon, France (L.P., J.G.); and Department of Tumor Immunology, Wielkopolska Cancer Center, Poznan, Poland (D.W.K.)
Matthias Sendler
Research Center of Pharmacology and Experimental Therapeutics (P.K.N., T.H., K.K., M.G., G.J., C.R., D.R., H.K.K., C.A.R.), Institute of Pharmacy (S.M., C.A.R.), and Department of Internal Medicine A (M.S., F.U.W., J.M., M.M.L.), Ernst-Moritz-Arndt-University, Greifswald, Germany; Laboratoire de Toxicologie, Faculté de Pharmacie de Lyon, Université de Lyon, Lyon, France (L.P., J.G.); and Department of Tumor Immunology, Wielkopolska Cancer Center, Poznan, Poland (D.W.K.)
Gabriele Jedlitschky
Research Center of Pharmacology and Experimental Therapeutics (P.K.N., T.H., K.K., M.G., G.J., C.R., D.R., H.K.K., C.A.R.), Institute of Pharmacy (S.M., C.A.R.), and Department of Internal Medicine A (M.S., F.U.W., J.M., M.M.L.), Ernst-Moritz-Arndt-University, Greifswald, Germany; Laboratoire de Toxicologie, Faculté de Pharmacie de Lyon, Université de Lyon, Lyon, France (L.P., J.G.); and Department of Tumor Immunology, Wielkopolska Cancer Center, Poznan, Poland (D.W.K.)
Christian Rimmbach
Research Center of Pharmacology and Experimental Therapeutics (P.K.N., T.H., K.K., M.G., G.J., C.R., D.R., H.K.K., C.A.R.), Institute of Pharmacy (S.M., C.A.R.), and Department of Internal Medicine A (M.S., F.U.W., J.M., M.M.L.), Ernst-Moritz-Arndt-University, Greifswald, Germany; Laboratoire de Toxicologie, Faculté de Pharmacie de Lyon, Université de Lyon, Lyon, France (L.P., J.G.); and Department of Tumor Immunology, Wielkopolska Cancer Center, Poznan, Poland (D.W.K.)
Dieter Rosskopf
Research Center of Pharmacology and Experimental Therapeutics (P.K.N., T.H., K.K., M.G., G.J., C.R., D.R., H.K.K., C.A.R.), Institute of Pharmacy (S.M., C.A.R.), and Department of Internal Medicine A (M.S., F.U.W., J.M., M.M.L.), Ernst-Moritz-Arndt-University, Greifswald, Germany; Laboratoire de Toxicologie, Faculté de Pharmacie de Lyon, Université de Lyon, Lyon, France (L.P., J.G.); and Department of Tumor Immunology, Wielkopolska Cancer Center, Poznan, Poland (D.W.K.)
Dariusz W. Kowalczyk
Research Center of Pharmacology and Experimental Therapeutics (P.K.N., T.H., K.K., M.G., G.J., C.R., D.R., H.K.K., C.A.R.), Institute of Pharmacy (S.M., C.A.R.), and Department of Internal Medicine A (M.S., F.U.W., J.M., M.M.L.), Ernst-Moritz-Arndt-University, Greifswald, Germany; Laboratoire de Toxicologie, Faculté de Pharmacie de Lyon, Université de Lyon, Lyon, France (L.P., J.G.); and Department of Tumor Immunology, Wielkopolska Cancer Center, Poznan, Poland (D.W.K.)
Heyo K. Kroemer
Research Center of Pharmacology and Experimental Therapeutics (P.K.N., T.H., K.K., M.G., G.J., C.R., D.R., H.K.K., C.A.R.), Institute of Pharmacy (S.M., C.A.R.), and Department of Internal Medicine A (M.S., F.U.W., J.M., M.M.L.), Ernst-Moritz-Arndt-University, Greifswald, Germany; Laboratoire de Toxicologie, Faculté de Pharmacie de Lyon, Université de Lyon, Lyon, France (L.P., J.G.); and Department of Tumor Immunology, Wielkopolska Cancer Center, Poznan, Poland (D.W.K.)
Frank U. Weiss
Research Center of Pharmacology and Experimental Therapeutics (P.K.N., T.H., K.K., M.G., G.J., C.R., D.R., H.K.K., C.A.R.), Institute of Pharmacy (S.M., C.A.R.), and Department of Internal Medicine A (M.S., F.U.W., J.M., M.M.L.), Ernst-Moritz-Arndt-University, Greifswald, Germany; Laboratoire de Toxicologie, Faculté de Pharmacie de Lyon, Université de Lyon, Lyon, France (L.P., J.G.); and Department of Tumor Immunology, Wielkopolska Cancer Center, Poznan, Poland (D.W.K.)
Julia Mayerle
Research Center of Pharmacology and Experimental Therapeutics (P.K.N., T.H., K.K., M.G., G.J., C.R., D.R., H.K.K., C.A.R.), Institute of Pharmacy (S.M., C.A.R.), and Department of Internal Medicine A (M.S., F.U.W., J.M., M.M.L.), Ernst-Moritz-Arndt-University, Greifswald, Germany; Laboratoire de Toxicologie, Faculté de Pharmacie de Lyon, Université de Lyon, Lyon, France (L.P., J.G.); and Department of Tumor Immunology, Wielkopolska Cancer Center, Poznan, Poland (D.W.K.)
Markus M. Lerch
Research Center of Pharmacology and Experimental Therapeutics (P.K.N., T.H., K.K., M.G., G.J., C.R., D.R., H.K.K., C.A.R.), Institute of Pharmacy (S.M., C.A.R.), and Department of Internal Medicine A (M.S., F.U.W., J.M., M.M.L.), Ernst-Moritz-Arndt-University, Greifswald, Germany; Laboratoire de Toxicologie, Faculté de Pharmacie de Lyon, Université de Lyon, Lyon, France (L.P., J.G.); and Department of Tumor Immunology, Wielkopolska Cancer Center, Poznan, Poland (D.W.K.)
Christoph A. Ritter
Research Center of Pharmacology and Experimental Therapeutics (P.K.N., T.H., K.K., M.G., G.J., C.R., D.R., H.K.K., C.A.R.), Institute of Pharmacy (S.M., C.A.R.), and Department of Internal Medicine A (M.S., F.U.W., J.M., M.M.L.), Ernst-Moritz-Arndt-University, Greifswald, Germany; Laboratoire de Toxicologie, Faculté de Pharmacie de Lyon, Université de Lyon, Lyon, France (L.P., J.G.); and Department of Tumor Immunology, Wielkopolska Cancer Center, Poznan, Poland (D.W.K.)
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleArticle
Drug Efflux Transporter Multidrug Resistance-Associated Protein 5 Affects Sensitivity of Pancreatic Cancer Cell Lines to the Nucleoside Anticancer Drug 5-Fluorouracil
Praveen K. Nambaru, Tobias Hübner, Kathleen Köck, Steffen Mews, Markus Grube, Léa Payen, Jérôme Guitton, Matthias Sendler, Gabriele Jedlitschky, Christian Rimmbach, Dieter Rosskopf, Dariusz W. Kowalczyk, Heyo K. Kroemer, Frank U. Weiss, Julia Mayerle, Markus M. Lerch and Christoph A. Ritter
Drug Metabolism and Disposition January 1, 2011, 39 (1) 132-139; DOI: https://doi.org/10.1124/dmd.110.033613
Research ArticleArticle
Drug Efflux Transporter Multidrug Resistance-Associated Protein 5 Affects Sensitivity of Pancreatic Cancer Cell Lines to the Nucleoside Anticancer Drug 5-Fluorouracil
Praveen K. Nambaru, Tobias Hübner, Kathleen Köck, Steffen Mews, Markus Grube, Léa Payen, Jérôme Guitton, Matthias Sendler, Gabriele Jedlitschky, Christian Rimmbach, Dieter Rosskopf, Dariusz W. Kowalczyk, Heyo K. Kroemer, Frank U. Weiss, Julia Mayerle, Markus M. Lerch and Christoph A. Ritter
Drug Metabolism and Disposition January 1, 2011, 39 (1) 132-139; DOI: https://doi.org/10.1124/dmd.110.033613
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement